Copy to clipboard 
SeaSpine announced 4Q17 revenue of US $34.0MM, +4.5% vs. 4Q16, and 2017 revenue of $131.8MM, +2.3% vs. 2016. These final figures came in below ranges announced preliminarily in 1Q17.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Spine | $15.9 | $15.9 | $0.0 | 0.0% |
| Orthobiologics | $18.1 | $16.6 | $1.5 | 9.0% |
| Total | $34.0 | $32.5 | $1.5 | 4.5% |
| 2017 | 2016 | $ Change | % Change | |
| Spine | $62.7 | $62.6 | $0.1 | 0.1% |
| Orthobiologics | $69.2 | $66.2 | $2.9 | 4.4% |
| Total | $131.8 | $128.8 | $3.0 | 2.3% |
Strong biologics growth in the U.S. was driven by new distribution. The company introduced the first internally-developed biologic products in nearly eight years. Of four new biologics, SPNE entered limited launch in 4Q alone for OsteoStrand and OsteoStrand Plus demineralized bone fibers as well as OsteoBallast demineralized bone matrix in resorbable mesh.
Spine sales continued to be affected by price declines and decreased use of legacy systems, though offset by recently-launched products like Mariner and Shoreline. In hardware, after the quarter’s close, they expanded the Ventura NanoMetalene interbody line to include sizes for a larger range of posterior procedures and more patient anatomies. Recently-launched products accounted for ~40% of U.S. implant revenue in 4Q, and 30% for the whole year. SeaSpine is on track to generate >50% of 2018 revenue from products launched within the past four years.
Distributors brought on since late 2016 contributed 25% to U.S. 4Q revenue and almost 20% of U.S. revenue for the full year.
For 2018, leadership cites full-year revenue guidance in a range from $135MM to $139MM, with 2H18 growth outpacing that of 1H18. The target is set for eight products or line extensions to launch within the year, with an increasing number of sets deployed with each launch.
Source: SeaSpine
SeaSpine announced 4Q17 revenue of US $34.0MM, +4.5% vs. 4Q16, and 2017 revenue of $131.8MM, +2.3% vs. 2016. These final figures came in below ranges announced preliminarily in 1Q17.
Q17
Q16
$ Change
% Change
Spine...
SeaSpine announced 4Q17 revenue of US $34.0MM, +4.5% vs. 4Q16, and 2017 revenue of $131.8MM, +2.3% vs. 2016. These final figures came in below ranges announced preliminarily in 1Q17.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Spine | $15.9 | $15.9 | $0.0 | 0.0% |
| Orthobiologics | $18.1 | $16.6 | $1.5 | 9.0% |
| Total | $34.0 | $32.5 | $1.5 | 4.5% |
| 2017 | 2016 | $ Change | % Change | |
| Spine | $62.7 | $62.6 | $0.1 | 0.1% |
| Orthobiologics | $69.2 | $66.2 | $2.9 | 4.4% |
| Total | $131.8 | $128.8 | $3.0 | 2.3% |
Strong biologics growth in the U.S. was driven by new distribution. The company introduced the first internally-developed biologic products in nearly eight years. Of four new biologics, SPNE entered limited launch in 4Q alone for OsteoStrand and OsteoStrand Plus demineralized bone fibers as well as OsteoBallast demineralized bone matrix in resorbable mesh.
Spine sales continued to be affected by price declines and decreased use of legacy systems, though offset by recently-launched products like Mariner and Shoreline. In hardware, after the quarter’s close, they expanded the Ventura NanoMetalene interbody line to include sizes for a larger range of posterior procedures and more patient anatomies. Recently-launched products accounted for ~40% of U.S. implant revenue in 4Q, and 30% for the whole year. SeaSpine is on track to generate >50% of 2018 revenue from products launched within the past four years.
Distributors brought on since late 2016 contributed 25% to U.S. 4Q revenue and almost 20% of U.S. revenue for the full year.
For 2018, leadership cites full-year revenue guidance in a range from $135MM to $139MM, with 2H18 growth outpacing that of 1H18. The target is set for eight products or line extensions to launch within the year, with an increasing number of sets deployed with each launch.
Source: SeaSpine
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
